KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Pacific Biosciences Of California (PACB) over the last 17 years, with Q3 2025 value amounting to $408.9 million.

  • Pacific Biosciences Of California's Non-Current Assets fell 5277.04% to $408.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year decrease of 4653.82%. This contributed to the annual value of $764.8 million for FY2024, which is 2382.55% down from last year.
  • Pacific Biosciences Of California's Non-Current Assets amounted to $408.9 million in Q3 2025, which was down 5277.04% from $412.1 million recorded in Q2 2025.
  • Over the past 5 years, Pacific Biosciences Of California's Non-Current Assets peaked at $1.0 billion during Q3 2023, and registered a low of $56.6 million during Q2 2021.
  • Moreover, its 5-year median value for Non-Current Assets was $905.1 million (2022), whereas its average is $744.5 million.
  • In the last 5 years, Pacific Biosciences Of California's Non-Current Assets soared by 149917.91% in 2022 and then plummeted by 5811.59% in 2025.
  • Pacific Biosciences Of California's Non-Current Assets (Quarter) stood at $905.8 million in 2021, then grew by 1.01% to $915.0 million in 2022, then increased by 9.72% to $1.0 billion in 2023, then dropped by 23.83% to $764.8 million in 2024, then crashed by 46.53% to $408.9 million in 2025.
  • Its last three reported values are $408.9 million in Q3 2025, $412.1 million for Q2 2025, and $415.9 million during Q1 2025.